• Ziopharm Oncology Inc., of New York, said an independent data monitoring committee unanimously recommended continuation of its international, randomized, double-blind, placebo-controlled Phase III trial of palifosfamide (Zymafos, or ZIO-201), dubbed PICASSO 3, in front-line metastatic soft tissue sarcoma – the third such review and recommendation by the committee.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST